David Sutter, MD
Interventional Cardiology · Ypsilanti, MINPI 1457512063
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,905 of the $2,166 with a category attached, or 87.9%. 18 manufacturers reported payments, led by Boston Scientific at 28.4% of the total. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.
Across 80 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$616
- Edwards Lifesciences$426
- Abbott$267
- Abiomed$223
- Novo Nordisk$95
- Novartis$82
- plus $458 from 12 others
Across 104 payments — averaging $2441.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$164K
- Boehringer Ingelheim International GmbH$37K
- Boehringer Ingelheim Pharma GmbH & Co.kg$26K
- Alnylam Pharmaceuticals Inc.$20K
- Boston Scientific$7K
What the payments were for
- Travel & lodging$26112%
- Food & beverage$1,90588%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 38 | $616 |
| Edwards Lifesciences | 4 | $426 |
| Abbott | 2 | $267 |
| Abiomed | 6 | $223 |
| Novo Nordisk | 3 | $95 |
| Novartis | 5 | $82 |
| Cardiovascular Systems Inc. | 4 | $75 |
| Teleflex LLC | 4 | $70 |
| Amgen | 3 | $62 |
| Atricure, Inc. | 1 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Cordis US CORP. | 2 | $39 |
| Biotronik Inc. | 1 | $25 |
| Biosense Webster, Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $21 |
| Janssen Scientific Affairs, LLC | 1 | $19 |
| Terumo Medical Corporation | 1 | $19 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PASCAL$261
- Xience Sierra Coronary Stent System$253
- CROSSBOSS$140
- Impella$107
How this compares
$2,166 in reported general payments places this provider in the 20th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 232 | $255,309 |
| XareltoRivaroxaban | 79 | $81,876 |
| JardianceEmpagliflozin | 46 | $60,204 |
| EntrestoSacubitril/Valsartan | 38 | $49,130 |
| Repatha SureclickEvolocumab | 38 | $40,230 |
| FarxigaDapagliflozin Propanediol | 24 | $19,195 |
| BrilintaTicagrelor | 23 | $15,787 |
| Icosapent Ethyl | 28 | $14,303 |
| Ezetimibe | 302 | $7,031 |
| Atorvastatin Calcium | 415 | $5,929 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 63 | $5,438 |
| Rosuvastatin Calcium | 228 | $4,991 |
| Metoprolol Succinate | 293 | $4,961 |
| Carvedilol | 246 | $3,303 |
| Losartan Potassium | 245 | $2,923 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $16 | $255,309232 claims |
| Johnson & JohnsonXarelto | $21 | $81,87679 claims |
| NovartisEntresto | $82 | $49,13038 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Ypsilanti
- Javier ValleYpsilanti$155K
- Herbert AronowYpsilanti$25K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Safwan KassasSaginaw$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.